Certara, Inc. (NASDAQ:CERT) Receives $17.08 Average Price Target from Brokerages

Shares of Certara, Inc. (NASDAQ:CERT) have earned a consensus rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $17.08.

Several research analysts have recently weighed in on CERT shares. KeyCorp decreased their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Robert W. Baird decreased their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Barclays dropped their price target on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 15th. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday, September 27th.

Certara Stock Performance

NASDAQ:CERT opened at $10.54 on Thursday. The business’s fifty day moving average is $11.58 and its 200 day moving average is $14.28. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -27.03, a PEG ratio of 5.40 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. Certara has a 52-week low of $10.35 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. During the same quarter in the prior year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Research analysts predict that Certara will post 0.27 EPS for the current year.

Insider Buying and Selling

In other Certara news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Sei Investments Co. grew its holdings in Certara by 12.4% in the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock worth $12,793,000 after acquiring an additional 79,013 shares during the last quarter. Geneva Capital Management LLC increased its holdings in Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after purchasing an additional 579,349 shares during the period. Wasatch Advisors LP raised its position in Certara by 23.4% during the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after purchasing an additional 932,598 shares during the last quarter. Motley Fool Asset Management LLC lifted its holdings in Certara by 94.0% in the 1st quarter. Motley Fool Asset Management LLC now owns 96,792 shares of the company’s stock worth $1,731,000 after buying an additional 46,897 shares during the period. Finally, Silvercrest Asset Management Group LLC grew its position in shares of Certara by 27.3% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock worth $9,231,000 after buying an additional 110,636 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.